Argo Dual SiRNA

Lead Asset:

Bispecific validated in vivo

• Safe and effective new drug for residual risk of cardiometabolic disease

• Globally, 450 million live with ASCVD and each year 20 million die from ASCVD

• Most are preventable

Clinical Entry Pathway

Rare orphan

Atherogenic Dyslipidaemias

Residual risk of Cardiometabolic disease

Mode of action

Bispecific siRNA enters the cell as a monomer, splitting into individual siRNAs in endosome, followed by target mRNA cleavage and reduction of target gene expression

Learn More ↗